The impact of lipoxin A.sub.4 (LXA.sub.4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF.alpha.)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1 10 nM, the LXA.sub.4 and ATL analogs each inhibited TNF.alpha.-stimulated superoxide anion generation and IL-1.beta. release by human PMN.